国际医药卫生导报
國際醫藥衛生導報
국제의약위생도보
INTERNATIONAL MEDICINE & HEALTH GUIDANCE NEWS
2010年
22期
2778-2781
,共4页
练小芬%李小玲%谌海兰%孙芳
練小芬%李小玲%諶海蘭%孫芳
련소분%리소령%심해란%손방
溶血磷脂酸(LPA)%人附睾蛋白4(HE4)%早期卵巢癌
溶血燐脂痠(LPA)%人附睪蛋白4(HE4)%早期卵巢癌
용혈린지산(LPA)%인부고단백4(HE4)%조기란소암
Lysophosphatidic acid%LPA%Human epididymis protein 4(HE4)%Early-stage ovarian cancer
目的 探讨溶血磷脂酸(LPA)、人附睾蛋白4(HE4)检测对卵巢癌早期诊断的价值.方法 测定121例女性血清样品,其中早期卵巢癌组31例,非恶性卵巢疾病组40例,健康体检女性50例,用定磷法、ELISA法分别检测血清LPA、HE4含量.结果 LPA、HE4含量在早期卵巢癌组分别为(12.24±6.16)μ mol/L、(102.8±167.3)pmol/L,均明显高于非恶性卵巢疾病组(2.32±1.03)μmol/L、(34.3±12.1)pmol/L和健康体检组(2.04±0.68)μ mol/L、(28.6±8.3)pmol/L,两组比较有极显著性差异(P<0.01).作为早期卵巢癌的实验诊断,LPA、HE4联合检测优于单项检测,其敏感性为96.8%、特异性为87.8%,准确度为90.1%.结论 LPA、HE4检测在卵巢癌的早期诊断具有重要的临床应用价值,二者联合检测更有利于卵巢癌的早期诊断.
目的 探討溶血燐脂痠(LPA)、人附睪蛋白4(HE4)檢測對卵巢癌早期診斷的價值.方法 測定121例女性血清樣品,其中早期卵巢癌組31例,非噁性卵巢疾病組40例,健康體檢女性50例,用定燐法、ELISA法分彆檢測血清LPA、HE4含量.結果 LPA、HE4含量在早期卵巢癌組分彆為(12.24±6.16)μ mol/L、(102.8±167.3)pmol/L,均明顯高于非噁性卵巢疾病組(2.32±1.03)μmol/L、(34.3±12.1)pmol/L和健康體檢組(2.04±0.68)μ mol/L、(28.6±8.3)pmol/L,兩組比較有極顯著性差異(P<0.01).作為早期卵巢癌的實驗診斷,LPA、HE4聯閤檢測優于單項檢測,其敏感性為96.8%、特異性為87.8%,準確度為90.1%.結論 LPA、HE4檢測在卵巢癌的早期診斷具有重要的臨床應用價值,二者聯閤檢測更有利于卵巢癌的早期診斷.
목적 탐토용혈린지산(LPA)、인부고단백4(HE4)검측대란소암조기진단적개치.방법 측정121례녀성혈청양품,기중조기란소암조31례,비악성란소질병조40례,건강체검녀성50례,용정린법、ELISA법분별검측혈청LPA、HE4함량.결과 LPA、HE4함량재조기란소암조분별위(12.24±6.16)μ mol/L、(102.8±167.3)pmol/L,균명현고우비악성란소질병조(2.32±1.03)μmol/L、(34.3±12.1)pmol/L화건강체검조(2.04±0.68)μ mol/L、(28.6±8.3)pmol/L,량조비교유겁현저성차이(P<0.01).작위조기란소암적실험진단,LPA、HE4연합검측우우단항검측,기민감성위96.8%、특이성위87.8%,준학도위90.1%.결론 LPA、HE4검측재란소암적조기진단구유중요적림상응용개치,이자연합검측경유리우란소암적조기진단.
Objective To explore the specific value of lysophosphatidic acid (LPA) and human epididymis protein 4 ( HE4 ) on the early diagnosis of ovarian cancer. Methods Among the 121female patients serum samples colleted from the local hospital, 31 cases are early ovarian cancer group, 40cases are the nonmalignant ovarian disease group, 50 cases are the healthy check-up female. By means of phosphorus and ELISA,We can analyse the content of LPA and HE4 in serum .Results The value of LPA and HE4 In early-stage ovarian cancer group are( 12.24 ± 6.16) μ mol/L and(102.8 ± 167.3)pmol/L,respectively, much higher than the nonmalignant ovarian disease' s(2.32 ± 1.03) μ mol/L、(34.3 ± 12.1)pmol/L and the health check-up' s(2.04 ± 0.68)μ mol/L、(28.6 ± 8.3)pmol/L, Significant difference (P< 0.01). As the early experimental diagnoses for ovarian cancer, the conbination test of LPA and HE4 is better than the any single test of them. The conbination test' s sensitivity is 96.8%, its specificity is 87.8%,its accuracy is 90.1%. Conclusion Detect the LPA and HE4 in the early diagnosis of ovarian cancer has important value for clinical applications, It' s superior than the single use for early diagnosis in ovarian cancer.